Download PDF
Deutsche Zeitschrift für Onkologie 2015; 47(2): 82-87
DOI: 10.1055/s-0035-1547551
Praxis
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Wie beeinflusst die Therapie solider epithelialer Tumore die im Blut zirkulierenden Tumorzellen?

Katharina Pachmann
Further Information

Publication History

Publication Date:
07 July 2015 (online)

    Permissions and Reprints

Zusammenfassung

Obgleich das operative Vorgehen insbesondere beim Brustkrebs dank der bahnbrechenden Erkenntnisse der Brüder Fisher sehr viel weniger eingreifend geworden ist als noch vor 50 Jahren, können doch durch die Manipulation Zellen ins periphere Blut ausgeschwemmt und durch die Entzündungs- und Heilungsvorgänge aktiviert werden. Möglicherweise bietet eine anti-inflammatorische Medikation hier nicht nur die Möglichkeit, Begleitprobleme zu mindern, sondern auch die Aktivierung der systemischen Tumorzellen zu verhindern. Eine Langzeitüberwachung kann unter und nach der endokrinen Therapie zur Entscheidung beitragen, ob diese nach den bisher empfohlenen 5 Jahren weitergeführt oder erneut aufgenommen werden soll. Bei sehr kleinen und nicht invasiven Tumoren könnte auch eine Überwachung der im Blut zirkulierenden Tumorzellen zur Therapieentscheidung beitragen.

Summary

Surgery in solid malignant tumours, especially in breast cancer has become much less radical due to the seminal findings of the Fisher brothers 50 years ago. In spite of this, cells from the tumour can be disseminated into the circulation and can become activated through inflammatory and wound healing processes. Possibly in the future, perioperative non-steroidal anti-inflammatory drugs may not only provide the change to reduce the adverse reactions to surgery but also to prevent activation of the circulating tumour cells. Monitoring of the behaviour of the circulating tumour cells during the course of disease during endocrine treatment might assist in decision making with respect to duration of this treatment. In very small tumours and those with low metastatic potential surveillance of the behaviour of the circulating tumour cells may help to decide when and how intensive treatment to apply.

Schlüsselwörter

Operation bei soliden Tumoren - im Blut zirkulierende Tumorzellen - Aktivierung - Metastasenbildung

Keywords

surgery in solid malignant tumours - circulating tumour cells - activation - metastasis
 

  • Literatur

  • 1 Andersen KG, Christensen KB, Kehlet H, Bidstup PE. The effect of pain on physical functioning after breast cancer treatment: development and validation of an assessment tool. Clin J Pain 2014; Oct 10
    PubMedGoogle Scholar
  • 2 Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aust Med J 1869; 14: 146
    PubMedGoogle Scholar
  • 3 Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, Neubauer H. Dormancy in breast cancer. Breast Cancer: Targets and Therapy. 2012. 4. 183-191
    Google Scholar
  • 4 Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. Br Med J 2005; 330: 217
    CrossrefPubMedGoogle Scholar
  • 5 Bonadonna G, Valagussa P, Veronesi U. Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer. J Clin Oncol 2008; 26: 342-4
    CrossrefPubMedGoogle Scholar
  • 6 Camara O, Kavallaris A, Nöschel H, Rengsberger M, Jörke C, Pachmann K. Seeding of epithelial cells into circulation during surgery for breast cancer. The fate of malignant and benign mobilized cells. World J Surg Oncol 2006; 4: 67
    CrossrefPubMedGoogle Scholar
  • 7 Chiarella P, Bruzzo J, Meiss RP, Ruggiero RA. Concomitant tumor resistance. Cancer Lett 2012; 324: 133-41
    CrossrefPubMedGoogle Scholar
  • 8 Doornebal CW, Vrijland K, Hau CS, Coffelt SB, Ciampricotti M, Jonkers J, de Visser KE, Hollmann MW. Morphine does not facilitate breast cancer progression in two preclinical mouse models for invasive lobular and HER2+ breast cancer. Pain 2015; Feb 13
    PubMedGoogle Scholar
  • 9 Dragun AE, Pan J, Riley EC, Kruse B, Wilson MR, Rai S, Jain D. Increasing use of elective mastectomy and contralateral prophylactic surgery among breast conservation candidates: a 14-year report from a comprehensive cancer center. Am J Clin Oncol 2013; 36: 375-80
    CrossrefPubMedGoogle Scholar
  • 10 Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978; 38: 2651-60
    PubMedGoogle Scholar
  • 11 Fisher B. Laboratory and clinical research in breast cancer – a personal adventure: The David A. Karnofsky Memorial Lecture. Cancer Res 1980; 40: 3863-3874
    PubMedGoogle Scholar
  • 12 Fisher B, Fisher ER. The organ distribution of disseminated 51Cr-labeled tumor cells. Cancer Res 1967; 27: 412-20
    PubMedGoogle Scholar
  • 13 Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347: 567-75
    CrossrefPubMedGoogle Scholar
  • 14 Fisher ER, Turnbull RB. The cytologic demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal carcinoma. Surg Gynecol Obstet 1955; 100: 102-108
    PubMedGoogle Scholar
  • 15 Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907; 46: 1-19
    CrossrefPubMedGoogle Scholar
  • 16 Henney JE, Devita VT. The evolution of primary multimodality treatment in resectable breast cancer. Cancer 1980; 46(4 Suppl): 999-1008
    CrossrefPubMedGoogle Scholar
  • 17 Jin J. Breast cancer screening: benefits and harms. JAMA 2014; 312: 2585
    CrossrefPubMedGoogle Scholar
  • 18 Julian TB, Venditti CA, Duggal S. Landmark clinical trials influencing surgical management of non-invasive and invasive breast cancer. Breast J 2015; 21: 60-6
    CrossrefPubMedGoogle Scholar
  • 19 Kopec JA, Colangelo LH, Land SR, Julian TB, Brown AM, Anderson SJ, Krag DN, Ashikaga T, Costantino JP, Wolmark N, Ganz PA. Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP Protocol B-32. J Support Oncol 2013; 11: 22-30
    PubMedGoogle Scholar
  • 20 Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA 2014; 312: 902-14
    CrossrefPubMedGoogle Scholar
  • 21 Niu DG, Peng F, Zhang W, Guan Z, Zhao HD, Li JL, Wang KL, Li TT, Zhang Y, Zheng FM, Xu F, Han QN, Gao P, Wen QP, Liu Q. Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer. Oncotarget 2015; 6: 3963-76
    CrossrefPubMedGoogle Scholar
  • 22 No authors Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance. Prescrire Int 2013; 22: 298-303
    PubMedGoogle Scholar
  • 23 Pachmann K, Clement JH, Schneider CP, Willen B, Camara O, Pachmann U, Höffken K. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 2005; 43: 617-627
    CrossrefPubMedGoogle Scholar
  • 24 Paget S. The distribution of secondary growths in cancer of the breast. The Lancet 1889; 133: 571-573
    CrossrefPubMedGoogle Scholar
  • 25 Pesce CE, Liederbach E, Czechura T, Winchester DJ, Yao K. MD. Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: A report from the National Cancer Data Base. J Am Coll Surg 2014; 219: 19-30
    CrossrefPubMedGoogle Scholar
  • 26 Piana R. Opioid-reduction strategy for postoperative pain after breast cancer surgery. A conversation with Patrick I. Borgen, MD. The ASCO Post 2015; 6 Issue 7
    PubMedGoogle Scholar
  • 27 Pizon M, Zimon D, Carl S, Pachmann U, Pachmann K, Camara O. Heterogeneity of circulating epithelial tumour cells from individual patients with respect to expression profiles and clonal growth (sphere formation) in breast cancer. ecancer 2013; 7: 343
    PubMedGoogle Scholar
  • 28 Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS, Baum M, Forget P, Dekock M, Pachmann K. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat 2012; 134: 881-8
    CrossrefPubMedGoogle Scholar
  • 29 Retsky M, Demicheli R, Hrushesky WJM, Forget P, De Kock M, Gukas I, Rogers RA, Baum M, Sukhatme V, Vaidya JS. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Curr Med Chem 2013; 20: 4163-4176
    CrossrefPubMedGoogle Scholar
  • 30 Rolle A, Günzel R, Pachmann U, Willen B, Höffken K, Pachmann K. Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cuncer monitored by MAINTRAC is a predictor for relapse: A preliminary report. World J Surg Oncol 2005; 3: 18
    CrossrefPubMedGoogle Scholar
  • 31 Schöne U, Überrück T, Altendorf-Hofmann A et al. Evaluation of circulating tumour cells in peripheral blood samples of patients with colorectal carcinoma using MAINTRAC. 131. Kongress Deutsche Gesellschaft für Chirurgie, Berlin Germany; 25–28 March 2014 (Abstract-ID:545)
    PubMedGoogle Scholar
  • 32 Tyzzer EE. Factors in the Production and Growth of tumor Metastases. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2099742/-fn1 J Med Res 1913; 28: 309-332
    PubMedGoogle Scholar
  • 33 Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227-32
    CrossrefPubMedGoogle Scholar
  • 34 Ye JC, Yan W, Christos PJ, Nori D, Ravi A. Equivalent survival with mastectomy or breast-conserving surgery plus radiation in young women aged < 40 years with early-stage breast cancer: a national registry-based stage-by-stage comparison. Clin Breast Cancer 2015; Apr 2 DOI: 10.1016/j.clbc.2015.03.012. [Epub ahead of print]
    PubMedGoogle Scholar
  • 35 Zahl PH, Gøtzsche PC, Mæhlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol 2011; 12: 1118-24
    CrossrefPubMedGoogle Scholar